Zhuhai Sailong Pharmaceutical Co Ltd
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pan… Read more
Zhuhai Sailong Pharmaceutical Co Ltd - Asset Resilience Ratio
Zhuhai Sailong Pharmaceutical Co Ltd (002898) has an Asset Resilience Ratio of 1.19% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how Zhuhai Sailong Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Zhuhai Sailong Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥10.00 Million | 1.19% |
| Total Liquid Assets | CN¥10.00 Million | 1.19% |
Asset Resilience Insights
- Limited Liquidity: Zhuhai Sailong Pharmaceutical Co Ltd maintains only 1.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhuhai Sailong Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhuhai Sailong Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Zhuhai Sailong Pharmaceutical Co Ltd (2020–2023)
The table below shows the annual Asset Resilience Ratio data for Zhuhai Sailong Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.26% | CN¥2.14 Million | CN¥813.84 Million | +2.33pp |
| 2022-12-31 | -2.07% | CN¥-17.52 Million | CN¥847.99 Million | -0.04pp |
| 2021-12-31 | -2.03% | CN¥-17.89 Million | CN¥882.78 Million | -- |
| 2020-12-31 | 0.00% | CN¥0.00 | CN¥813.96 Million | -- |